Novo Nordisk (NVO) Falls More Steeply Than Broader Market: What Investors Need to KnowZacks Investment Research • 09/23/26
Can Novo's Rare Disease Pipeline Add a New Growth Pillar Beyond GLP-1?Zacks Investment Research • 09/23/26
Launching The Allocation Compass: A Risk-Reward Approach To Portfolio AllocationSeeking Alpha • 09/23/26
Novo Nordisk Has a Fresh New Name -- but It Still Faces the Same Old ProblemsThe Motley Fool • 09/22/26
Novo's CagriSema Outshines Zepbound in Key Phase III Weight-Loss StudyZacks Investment Research • 09/22/26
European drugmakers call for faster trials, more spending to compete with US, ChinaReuters • 09/22/26
Novo's CEO Called Ozempic's Patent Cliff the "Elephant in the Room" Yesterday. Is the Stock Still a Buy?The Motley Fool • 09/22/26
Novo Nordisk Targets Five Multi-Blockbusters by 2030 as Oral Wegovy Gains TractionMarketBeat • 09/21/26
Novo Nordisk shares plunge over 7% as new targets fail to reassure investorsProactive Investors • 09/21/26
Novo's Sogroya Gains CHMP Nod for Idiopathic Short Stature in the EUZacks Investment Research • 09/21/26
Novo Nordisk Falls 7% as Post-Wegovy Growth Plan Fails to Ease Competition Fears; Eli Lilly Slips, Viking Therapeutics Edges Higher24/7 Wall Street • 09/21/26